What question did this study set out to answer?

To investigate the effect of immunoglobulin replacement therapy on infection risk, survival, and non-relapse mortality after CD19 CAR T-cell therapy.

December 8, 2025BloodOpen Access

Analysis of immune parameters and effect of immunoglobulin replacement therapy on infection, survival and non-relapse mortality following CD19 CAR T-cell therapy

View Full Paper

Ask AI

Bookmark

Authors

AKAmy A. KirkwoodCancer Research UK BGBrijesh GautamaUniversity Hospitals Bristol and Weston NHS Foundation Trust VDVismay DeshaniManchester Royal Infirmary

Discussion

Member takes

Implication

Retrospective analysis finds immunoglobulin replacement therapy does not reduce non-relapse mortality in CD19 CAR T patients, suggesting targeted use may be beneficial.

Key Points

To investigate the effect of immunoglobulin replacement therapy on infection risk, survival, and non-relapse mortality after CD19 CAR T-cell therapy.
Conducted a real-world, retrospective, multi-centre study
Included 430 patients treated with CD19 CAR T-cell therapy
Analyzed immune parameters and infection data pre and post therapy
Immunoglobulin replacement therapy did not significantly reduce non-relapse mortality
Survival rates were examined with median follow-up of 24 months
Distinct differences observed in infections post therapy, with varying pathogens

Cite This Study

Kirkwood et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4c8 https://doi.org/10.1182/blood-2025-714

View Full Paper

Ask AI

Bookmark

Implication

Retrospective analysis finds immunoglobulin replacement therapy does not reduce non-relapse mortality in CD19 CAR T patients, suggesting targeted use may be beneficial.

Analysis of immune parameters and effect of immunoglobulin replacement therapy on infection, survival and non-relapse mortality following CD19 CAR T-cell therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Analysis of immune parameters and effect of immunoglobulin replacement therapy on infection, survival and non-relapse mortality following CD19 CAR T-cell therapy

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider